Research Article

Identification of the Metabolomics Signature of Human Follicular Fluid from PCOS Women with Insulin Resistance

Ran Liu,1 Shun Bai,2 Shengxia Zheng,2 Xinyi Zhu,2 Yan Zhang,2 Bo Xu,2 and Weidong Zhao1

1Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
2Reproductive and Genetic Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China

Correspondence should be addressed to Bo Xu; bio_xubo@163.com and Weidong Zhao; victorzhao@163.com

Received 19 December 2021; Accepted 22 February 2022; Published 20 March 2022

Academic Editor: Ihtisham Bukhari

Copyright © 2022 Ran Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Context. Polycystic ovary syndrome (PCOS) is a gynecological endocrine disease, and approximately 60% of patients with PCOS have different degrees of insulin resistance (IR). The regulatory role of metabolic networks in human follicular fluid (FF) related to IR in PCOS remains unclear. Aims. To explore the effect of IR on the metabolism of PCOS by analyzing the changes in FF metabolites in PCOS patients who are undergoing assisted reproductive technology based on the metabonomic platform of ultraperformance gas chromatography coupled to mass spectrometry (GC/MS). Method. Eight PCOS patients with IR (PCOS-IR) and 8 PCOS patients without IR (PCOS-NIR) were enrolled. All patients received controlled ovarian stimulation by using the gonadotropin-releasing hormone (GnRH) antagonist protocol, and the FF of a single dominant follicle was collected on the day of oocyte retrieval. The metabolite profiles of the FF were determined by GC/MS. Key Results. A total of 20 differentially expressed metabolites in FF were identified. Compared with levels in the PCOS-NIR group, stearic acid, palmitic acid, pentadecanoic acid, stigmasterol, citric acid, isocitric acid, thymine, and pyruvic acid in FF were significantly increased in the PCOS-IR group. Lithocholic acid and sinapinic acid in FF decreased significantly. The affected metabolic pathways with potential regulatory roles were identified by KEGG annotation. Conclusion. Compared with the PCOS-NIR group, the PCOS-IR group showed more significant metabolic abnormalities. Implications. These results will help us to understand the pathogenesis of PCOS combined with IR and will provide new clues for studying metabolic disorders associated with PCOS, e.g., IR.

1. Introduction

Polycystic ovary syndrome (PCOS) is a prevalent heterogeneous disease that is an endocrine and metabolic disorder in women worldwide. Hyperandrogenism, ovulation disorder, polycystic ovaries, and insulin resistance (IR) are common clinical features of PCOS [1]. However, the etiology and pathogenesis of PCOS are still unclear. IR and the associated compensatory hyperinsulinemia are common abnormalities in PCOS. IR has been proven to be related to abnormal glucose, amino acid, and lipid metabolism [2]. IR aggravates the symptoms of PCOS and increases the risk of complications such as cardiovascular disease and type 2 diabetes in PCOS [3]. In the present study, we used the homeostatic model assessment of insulin resistance (HOMA-IR) index, which is the simplest and most effective method, to evaluate IR.

Compared with genomics and proteomics, metabonomics is more related to physiology. PCOS causes changes in pathophysiological processes and finally leads to corresponding changes in metabolites. By analyzing some metabolites and comparing them between groups, we expect to find biomarkers of PCOS-IR, which will provide a better method for disease diagnosis.

The metabolic features of the biochemical status in the circulation can be reflected in follicular fluid (FF), which is the exudate of plasma. The metabolites required for oocyte growth and development accumulate in the FF, which
provides unique conditions for oocyte development [4]. Therefore, understanding the metabolic features of FF in PCOS patients with IR may help clarify the pathogenesis of PCOS-IR. We conducted FF metabolomic analysis to investigate the metabolic changes in the PCOS-IR and PCOS without IR (PCOS-NIR) groups using gas chromatography/mass spectrometry (GC/MS). We expect to identify the metabolic characteristics and biomarkers of PCOS-IR from the perspective of metabolomics.

2. Materials and Methods

2.1. Participants. The study individuals consisted of 16 patients with PCOS. These patients were divided into an IR group (8 cases, HOMA–IR ≥ 2.69) and an NIR group (8 cases, HOMA–IR < 2.69) according to the HOMA-IR. The women’s PCOS diagnoses were based on the 2003 Rotterdam criteria [5]. Each patient met at least two of the following criteria: (1) oligomenorrhea and/or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, and (3) polycystic ovaries following the exclusion of congenital adrenal hyperplasia, 21-hydroxylase-deficient nonclassical adrenal hyperplasia, androgen-secreting tumor, Cushings’s syndrome, and other related disorders. All patients received in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET) because of the couples’ sterility. The existence of serious and unstable physical diseases was the exclusion criterion for both groups.

2.2. Samples and Clinical Data Collection. All patients were Chinese females, and FF samples were obtained from The First Affiliated Hospital of USTC. All patients received the antagonist protocol to stimulate ovulation. When at least three follicles grew to approximately 18 mm in diameter, human chorionic gonadotropin (HCG) was administered. FF was collected 34–36 hours after HCG administration under the guidance of transvaginal ultrasound. At the first puncture of each ovary, clear FF was collected from a single large follicle. Each FF sample was centrifuged at 3000 g for 10 min. Aliquots were placed in a 1.5 mL Eppendorf tube and immediately frozen in a refrigerator at −80°C until use. Serum estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), fasting blood glucose, and fasting insulin were measured on days 2–5 of the menstrual cycle of women using an automated chemiluminescence system. The women’s weight and height were also measured, and their body mass index (BMI; weight (kg)/height (m²)) was calculated. HOMA-IR was calculated as fasting glucose (mmol/L) × fasting insulin (mIU/L)/22.5, and the critical point was 2.69 [6].

2.3. Sample Preparation and Derivatization. Samples stored at -80°C were thawed at room temperature. One microliter of sample was added to a 1.5 mL Eppendorf tube with 10 μL of 2-chloro-1-phenylalanine (0.3 mg/mL) dissolved in methanol as an internal standard, and the tube was vortexed for 10 s. Subsequently, 1 μL of an ice-cold mixture of acetonitrile-methanol (1/2, v/v) was added. After the mixtures were vortexed for 1 min, ultrasonicated at 26°C for 5 min and stored at -20°C for 10 min, the extract was centrifuged at 12,000 rpm at 4°C for 10 min. An aliquot of 1 μL of the supernatant was transferred to a glass sampling vial for vacuum drying. Subsequently, 80 μL of 15 mg/mL methoxyamine hydrochloride in pyridine was added. The mixture was vortexed vigorously for 2 min and incubated at 37°C for 1.5 hours. Eighty microliters of N,O-bis(trimethylsilyl)-trifluoroacetonamide (BSTFA) (with 1% trimethylchlorosilane (TMCS)) and 20 μL of n-hexane were added to the mixture, which was vortexed vigorously for 2 min and then derivatized for 1 hour at 70°C. The samples were incubated for 30 min before GC–MS analysis.

2.4. GC–MS Analysis. GC–MS analysis was performed using an Agilent 7890B gas chromatography system with an Agilent 5977A MSD system (Agilent Technologies Inc., CA, USA). An ADB-5ms fused-silica capillary column (30 m × 0.25 mm i.d., 0.25 μm film thickness; Agilent J & W Scientific, Folsom, CA, USA) was used to separate the derivatives. Helium was used as the carrier gas at a constant flow rate of 1 mL/min. The injector temperature was set to 260°C. A 1.0 μL sample was injected in splitless mode. The initial oven temperature was 60°C, raised to 270°C at a rate of 10°C/min, raised to 305°C at a rate of 20°C/min, and finally raised to 305°C and held for 5 min. The collision energy was 70 eV. Mass spectrometric data were acquired using electron impact ionization (70 eV) in full scan mode (m/z 50–500).

2.5. Data Preprocessing and Statistical Analysis. Raw data from datasets, including sample information, peak names (or retention time and m/z), and peak intensities, were log10 transformed, and the resulting data were then imported into the R rplps package. The data were processed using supervised orthogonal partial least-squares-discriminant analysis (OPLS-DA) to visualize the metabolic difference between the experimental group and the control group after mean centering and unit variance scaling. Variable importance in the projection (VIP) ranks the overall contribution of each variable to the OPLS-DA model, and those variables with VIP > 1 are considered relevant for group discrimination. Default 7-round cross-validation was used in this study. Two hundred response ranking tests were performed on the OPLS-DA model, and the corresponding OPLS-DA model was established to obtain the R2 and Q2 values of the random model to measure whether the model was overfitted. Differential metabolites were obtained according to the combination of the statistically significant threshold of VIP values obtained from the OPLS-DA model and P values from Student’s t-test on the normalized peak areas of different groups. Metabolites with VIP values greater than 1.0 and P values less than 0.05 were regarded as differential metabolites.

2.6. Functional Enrichment Analysis and Pathway Topology Analysis. The metabolites with significant changes between the two groups were analyzed to uncover the metabolic pathways and further biological explanation. Potential targets were selected through the P value of pathway...
enrichment analysis and the influence value of pathway topology analysis.

2.7. Statistical Analysis. All values are presented as the mean ± SEM (standard error of the mean), and all data were analyzed by Student’s t-test or ANOVA. P < 0.05 was considered statistically significant. All statistical tests were performed using the GraphPad Prism software, version 6.0 (GraphPad Software Inc., San Diego, CA, USA).

3. Results

3.1. Clinical Characteristics. The characteristics of the patients in the PCOS-IR and PCOS-NIR groups are summarized in Table 1. We found no differences in terms of mean age (26.6 ± 4.3 years vs. 28.4 ± 3.7 years, P = 0.14) or basic sex hormone levels between the two groups. However, the PCOS-IR patients had a significantly higher BMI (23.1 ± 2.9 kg/m² vs. 20.8 ± 1.4 kg/m², P = 0.033) and fasting insulin levels (125.2 ± 35.4 mIU/L vs. 60.5 ± 21.2 mIU/L, P = 0.008) than the PCOS-NIR patients.

3.2. Identification of Metabolites and Data Analysis. Principal component analysis (PCA) is a type of unsupervised analysis that reflects the original situation of the data (R²X = 0.548; Figure 1(a)). Supervised OPLS-DA was used to filter out the noise irrelevant to the classification information, improve the analytical ability of the model, and highlight the differences between groups (Q² = 0.34, R²Y = 0.332, and R²X = 0.988; Figure 1(b)). To prevent overfitting of the model, sevenfold cross-validation and 200 response permutation testing (RPT) were used to investigate the quality of the model. The supervised model was protected against overfitting by Q² intercepting the y-axis at −0.059 (Figure 1(c)). Hierarchical clustering was used to analyze the expression levels of all significantly different metabolites (Figure 2). In addition, the Pearson correlation coefficient was used to measure the degree of linear correlation between the two metabolites (Figure 3). The above results show that there are significant metabolic differences between PCOS-IR and PCOS-NIR patients. In the present study, a total of 20 differential metabolites were identified (VIP > 1.0, P < 0.05), which are summarized in Table 2. The citric acid, isocitric acid, stearic acid, palmitic acid, pentadecanoic acid, stigmasterol, thymine, and pyruvic acid levels were significantly elevated, whereas the lathocholic acid and sinapinic acid levels were decreased in PCOS-IR patients. These changed metabolites may be related to PCOS-IR.

3.3. Metabolic Pathway Analysis. Metabolic pathway analysis of differential metabolites is helpful for understanding the metabolic mechanisms of the differential metabolites. In this study, the metabolic pathway enrichment of differential metabolites was analyzed based on the KEGG database. The significantly enriched pathways were selected for the bubble plot (Figure 4(a)) and metabolic pathway enrichment map (Figure 4(b)). The P value for the metabolic pathway represents the significance of the enrichment of that metabolic pathway. P ≤ 0.05 was taken as the threshold. The affected metabolic pathways in PCOS-IR patients included the abnormal citrate cycle (TCA), amino acid biosynthesis, glucagon metabolic pathway, and fatty acid biosynthesis. The above results indicated that a variety of metabolic pathways were associated with PCOS-IR pathogenesis. These results confirmed the accuracy of GC–MS analysis for the detection of variations in the levels of low-concentration metabolites, which are difficult to detect with traditional methods but are often important biomarkers and indicators of metabolic defects. The differentiated metabolism in the FF of PCOS-IR patients compared with that in the PCOS-NIR patient is summarized in Figure 5, which shows the differential metabolic pathways and differential metabolites between the two groups that may be associated with PCOS-IR development. The differential metabolites were colored according to whether they were up- or downregulated. The metabolites marked in red are those determined to be upregulated in the experiment, and the green metabolites are the downregulated metabolites. Blue color represents no significant change in metabolites.

4. Discussion

The etiology of PCOS with IR is complex. The purpose of the present study was to investigate the metabolic characteristics of the FF of PCOS patients with IR undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET). The present study demonstrated the changes in metabolite profiles between PCOS-IR patients and PCOS-NIR patients, which reflected the metabolic heterogeneity among the PCOS patients. The results show that the BMI of PCOS-IR patients was significantly higher than that of the PCOS-NIR group. The levels of pyruvic acid, citric acid, isocitric acid, stearic acid, and palmitic acid were significantly higher, and the levels of lathocholic acid and sinapinic acid were significantly lower in the PCOS-IR group than in the PCOS-NIR group. In addition, the abnormal TCA cycle, amino acid biosynthesis, glucagon metabolic pathway, and fatty acid biosynthesis had significant impacts on the metabolic changes in PCOS patients with IR.

PCOS is not only a reproductive endocrine disease but also a metabolic disease that is frequently accompanied by IR and obesity [7]. The symptoms of IR are worsened with increasing BMI [8]. PCOS patients with IR have a more severe phenotype than PCOS patients without IR [7]. Niu et al. found that the level of free fatty acids (FFAs) in the PCOS group was significantly higher than that in the control group [9]. However, the previous study did not differentiate between patients with and without IR, and the samples were plasma samples from patients.

In terms of lipid metabolism, stearic acid, palmitic acid, and pentadecanoic acid were higher in patients with PCOS-IR than in patients with PCOS-NIR. Insulin can maintain the balance of lipid metabolism by inhibiting the release of FFAs from adipose tissue [10]. Specifically, inhibition of the lipid oxidation rate is weakened for patients with IR, leading to an increase in the concentration of FFAs in FF. There are dozens of FFAs in PCOS patients’ plasma that are related to IR [11]. The insulin receptor can be affected by palmitic acid, which significantly stimulates insulin secretion.
Table 1: Clinical characteristics of PCOS-IR and PCOS-NIR patients.

| Clinical characteristics   | Total (n=16) | PCOS-IR (n=8) | PCOS-NIR (n=8) | P     |
|---------------------------|--------------|---------------|----------------|-------|
| Age (years), mean ± s.d.  | 27.5 ± 4.0   | 26.6 ± 4.3    | 28.4 ± 3.7     | 0.14  |
| BMI (kg/m²), mean ± s.d.  | 22.0 ± 2.5   | 23.1 ± 2.9    | 20.8 ± 1.4     | 0.033 |
| E2 (pg/mL), mean ± s.d.   | 45.8 ± 16.5  | 49.3 ± 21.4   | 42.4 ± 9.8     | 0.48  |
| FSH (ng/mL), mean ± s.d.  | 6.7 ± 1.4    | 6.3 ± 1.8     | 7.0 ± 0.8      | 0.37  |
| LH (ng/mL), mean ± s.d.   | 8.9 ± 4.4    | 9.2 ± 5.6     | 8.6 ± 3.1      | 0.82  |
| LH/FSH, mean ± s.d.       | 1.4 ± 0.7    | 1.5 ± 1.0     | 1.2 ± 0.4      | 0.55  |
| T (ng/mL), mean ± s.d.    | 0.7 ± 0.4    | 0.6 ± 0.4     | 0.8 ± 0.3      | 0.47  |
| Fasting glucose (mmol/L), mean ± s.d. | 4.8 ± 0.5 | 5.0 ± 0.3 | 4.6 ± 0.6 | 0.27 |
| Fasting insulin (mIU/L), mean ± s.d. | 92.8 ± 43.7 | 125.2 ± 35.4 | 60.5 ± 21.2 | 0.008 |
| HOMA-IR, mean ± s.d.      | 2.8 ± 1.5    | 3.9 ± 1.2     | 1.8 ± 0.6      | 0.0098|

Continuous variables are expressed as the mean ± standard deviation (SD). Student’s t-test was used for comparisons between groups. BMI: body mass index; E2: estradiol; FSH: follicle-stimulating hormone; LH: luteinizing hormone; T: testosterone; HOMA-IR: homeostatic model index of insulin resistance.

Figure 1: PCOS-IR patients and PCOS-NIR patients exhibited distinct metabolic characteristics. Principal component analysis (PCA) score plots were drawn according to the metabolic profiling information obtained from follicular fluid (FF) of PCOS-IR and PCOS-NIR patients (R²X = 0.548; (a)). (b) Orthogonal projections to latent structures–discriminant analysis (OPLS-DA) score plots were drawn according to the metabolic profiling information obtained from the FF of PCOS-IR and PCOS-NIR patients (Q² = 0.34, R²Y = 0.332, and R²X = 0.988). The purple dots indicate PCOS-IR patients (IR), and the yellow dots indicate PCOS-NIR patients (NIR). (c) The OPLS-DA model was constructed by the permutation test (R² = 0.983 and Q² = −0.059). The green dots indicate R², and the blue dots indicate Q².
Figure 2: Heat map of different metabolites. The relationships between samples and the expression differences in metabolites among different samples are visually displayed. The color from blue to red indicates that the abundance of metabolites ranged from low to high. The ordinate represents the differential metabolite, and the abscissa represents the sample name. C1-C8 represent each sample of the PCOS-IR group, and D1-D8 represent each sample of the PCOS-NIR group.

Figure 3: Correlation analysis of different metabolites. The Pearson correlation coefficient was used to measure the degree of linear correlation between the two metabolites; red indicates a positive correlation, and blue indicates a negative correlation.
and produces hyperinsulinemia, leading to the promotion of the occurrence of type 2 diabetes [12]. In addition, Matsu-
za et al. reported that the increase in palmitic acid and stearic acid as well as the process of converting palmitic acid to stearic acid is closely related to the occurrence of IR [13, 14]. Pentadecanoic acid may be formed from palmitic acid after intermediate hydroxylation [15]. Therefore, the increase in pentadecanoic acid in patients with PCOS-IR may be related to the increase in palmitic acid. It is speculated that the disorder of fatty acid biosynthesis in the FF of PCOS patients is closely related to IR.

Additionally, the present study showed that patients with PCOS-IR had higher levels of pyruvate, citric acid, and isocitric acid and an abnormal TCA cycle, which is the last common pathway of sugar, lipid, and amino acid metabolism. Pyruvate and isocitric acid are the main intermediate products in this cycle. Pyruvate acid, as the starting substrate for the TCA cycle and the final product of glycolysis, plays a key role in intermediary metabolism. Elevated pyruvate and fatty acid levels not only reflect the strengthening of glycolysis but also reflect the acceleration of fatty acid synthesis [16]. Pyruvate accumulation in the local tissue environment seems to be a crucial early response mechanism to hypergly-
cemia. Studies have found that cumulus cells in patients with PCOS show insufficiencies in the TCA cycle [17]. In addi-
tion, Rice et al. reported impaired glucose metabolism of granulosa luteal cells in PCOS patients [18]. Therefore, abnormal glucose metabolism and the TCA cycle may also be found in the FF of PCOS patients. Moreover, abnormal insulin levels in PCOS patients lead to decreased glucose uptake in the ovary and follicle [19]. More serious abnor-
malities in glucose metabolism and the TCA cycle may be present in patients with PCOS-IR.

Recent studies have shown that bile acid has some influence on the pathogenesis of diabetes. Bile acid metab-
olism is mainly mediated by bile acid nuclear receptors such as farnesoid X receptor (FXR) and membrane recep-
tor G protein coupled receptor (TGR5), which have an effect on the secretion of endocrine factors such as insulin and glucagon [20]. Among all the classes of bile acids, lithocholic acid (LCA) is the most effective activator of TGR5. Katsuma et al. showed that TGR5 can stimulate the production of glucagon-like peptide-1 (GLP-1), which exists in intestinal endocrine cell lines and prevents IR [21]. However, insulin can inhibit the rate-limiting enzyme of bile acid synthesis, namely, 7α hydroxylase, thereby reducing the synthesis of bile acid. Therefore, bile acids play important roles in the control of glucose metabolism

| Metabolite name                        | HMDB          | Class                         | VIP   | P value  | log2(FC) |
|----------------------------------------|---------------|-------------------------------|-------|----------|----------|
| Lithocholic acid                       | HMDB0000761   | Lipids and lipid-like molecules | 4.22019 | 8.41 × 10^{-4} | -3.03 |
| Citraconic acid                        | HMDB0000634   | Fatty acyls                   | 3.5403 | 1.71 × 10^{-4} | 1.27 |
| Dehydroascorbic acid                   | HMDB0001264   | Lactones                      | 3.3846 | 3.55 × 10^{-3} | 1.57 |
| Hydrocinnamic acid                     | HMDB0000764   | Phenylpropanoic acids         | 3.19849 | 1.14 × 10^{-3} | 1.09 |
| Isoxanthopterin                        | HMDB000704    | Pteridines and derivatives    | 2.86554 | 3.86 × 10^{-3} | 1.07 |
| Isocitric acid                         | HMDB0000193   | Carboxylic acids and derivatives | 2.28663 | 1.72 × 10^{-3} | 0.69 |
| 3-Amino-2-piperidone                   | HMDB000323    | Carboxylic acids and derivatives | 1.92061 | 5.04 × 10^{-3} | -0.60 |
| Ceroticinic acid                       | HMDB0002356   | Fatty acyls                   | 1.78952 | 2.39 × 10^{-2} | 0.47 |
| Urocanic acid                          | HMDB000301    | Azoles                        | 1.66985 | 3.60 × 10^{-2} | -0.77 |
| Isonicotinic acid                      | HMDB000665    | Pyridines and derivatives     | 1.65114 | 1.83 × 10^{-2} | 0.53 |
| Stigmasterol                           | HMDB0000937   | Steroids and steroid derivatives | 1.44124 | 4.80 × 10^{-2} | 0.42 |
| Heptadecanoic acid                     | HMDB0002259   | Fatty acyls                   | 1.40184 | 8.77 × 10^{-4} | 0.24 |
| Stearic acid                           | HMDB0000827   | Fatty acyls                   | 1.32349 | 3.51 × 10^{-4} | 0.21 |
| Sinapinic acid                         | HMDB0032616   | Cinnamic acids and derivatives | 1.28220 | 4.96 × 10^{-3} | -0.23 |
| Pyruvic acid                           | HMDB0000243   | Keto acids and derivatives    | 1.27191 | 4.05 × 10^{-2} | 0.30 |
| Thymine                                | HMDB0000262   | Diazines                      | 1.24689 | 1.64 × 10^{-2} | 0.24 |
| 5′-Deoxy-5′-methylthioadenosine        | HMDB001173    | 5′-Deoxyribonucleosides       | 1.20419 | 1.70 × 10^{-3} | -0.18 |
| Pentadecanoic acid                     | HMDB0000826   | Fatty acyls                   | 1.06299 | 1.12 × 10^{-2} | 0.17 |
| Palmitic acid                          | HMDB0000220   | Fatty acyls                   | 1.04755 | 1.15 × 10^{-2} | 0.17 |
| Cytosine                               | HMDB0000630   | Diazines                      | 1.03637 | 2.10 × 10^{-2} | 0.19 |

The combination of multidimensional analysis and unidimensional analysis was used to screen the differential metabolites between the groups. VIP shows the variable weight value obtained from the OPLS-DA model with a cutoff of 1.0. The greater the VIP is, the greater the contribution of the variable to the grouping. P values, calculated by t-tests, were used to evaluate whether the differences in variables between the two groups were significant. P < 0.05 indicates a significant difference. The log2(FC) was calculated as the ratio of the average expression of metabolites in the two groups of samples. A positive value indicates an increase, and a negative value indicates a decrease.
and IR. In this study, the lower level of lithocholic acid in the FF of IR patients may be related to IR. This result is consistent with previous studies [22].

The present study also showed that patients with PCOS-IR had lower levels of sinapinic acid. Sinapinic acid is a cinnamic acid derivative that has been evaluated for its potent antidiabetic activity [23]. The antihyperglycemic activity of sinapinic acid has been researched using a hyperglycemia model that was established by intraperitoneal injection of streptozotocin to destroy insulin-secreting pancreatic cells [23]. Sinapinic acid can also inhibit hydroperoxide formation more effectively by preventing lipid oxidation [24]. The hypolipidemic effect of erucic acid was also reported [25]. Therefore, the significant decrease in sinapinic acid levels in the PCOS-IR group may be related to IR and abnormal lipid metabolism.

The KEGG and pathway analysis results of this study identified differentially expressed glucagon signaling pathway terms as significantly enriched pathways. The results are shown in the bubble plot (Figure 4(a)). The ordinate is the name of the metabolic pathway, and the abscissa is the enrichment factor. The larger the rich factor is, the greater the enrichment degree is. The color from green to red indicates that the P value decreases; the larger the dot is, the more metabolites were enriched in the pathway. Metabolic pathway enrichment map. The P value indicated by the red line is 0.01, and that indicated by the blue line is 0.05. The smaller the P value is, the greater the value of \(-\log(P\ value)\).
pathway and amino acid metabolic pathways in the FF of PCOS-IR patients. The physiological function of glucagon is opposite to that of insulin, and together with insulin, it regulates energy metabolism. Under physiological conditions, insulin inhibits glucagon secretion, but in the case of IR, the glucagon signaling pathway is damaged. The leucine, isoleucine, and valine biosynthesis pathways were differentially expressed between the two groups. Both valine and leucine belong to the pyruvate group of amino acids. Abnormally elevated pyruvate can potentially accelerate the biosynthesis of valine, leucine, and isoleucine [16]. To compensate for the abnormal TCA cycle, the catabolism of valine, leucine, and isoleucine may also be accelerated, which explains why there was no significant difference in amino acid metabolites between the groups. Studies have found a major impact of disordered amino acid metabolism on the development of PCOS, and the difference in the amino acid biosynthesis pathway between groups in this study may further reflect that the amino acid biosynthesis pathway is closely related to the pathogenesis of PCOS patients with IR [26]. Some studies have reported potential amino acid biomarkers for IR. Zhao et al. reported that the level of leucine was positively correlated with IR [27]. Newgard et al. proposed that the circulating concentrations of valine and leucine were positively correlated with the development of obesity-related IR [28]. Wang et al. identified valine, leucine, and isoleucine as markers of IR [29]. Wurtz et al. considered that metabolic changes in branched chain amino acids, including valine, leucine, and isoleucine, preceded hyperglycemia [30]. Therefore, the abnormal biosynthetic pathways of valine, leucine, and isoleucine may be related to the pathogenesis of IR.

5. Conclusion

In summary, the results of this study identified pyruvic acid, citric acid, isocitric acid, stearic acid, and palmitic acid as differential metabolites in PCOS patients with IR. Furthermore, PCOS patients with IR had an abnormal TCA cycle, amino acid biosynthesis, glucagon metabolic pathway, and fatty acid biosynthesis. Disorders of amino acid metabolism, especially valine, leucine, and isoleucine biosynthesis pathways, and the TCA cycle might play crucial roles in the development of PCOS-IR. The differences in metabolism between the two groups that we observed provided us with significant biochemical information and metabolic characteristics that enabled the diagnosis of PCOS-IR. Metabolomics will provide another perspective to help clarify the molecular mechanism underlying PCOS-IR pathogenesis.

Data Availability

All raw data are available from the corresponding author upon request.

Ethical Approval

This study was approved by the Ethics Committees on Human Research of the First Hospital Affiliated with the University of Science and Technology of China (Approval ID 20160170).

Consent

All patients agreed to participate in this study and provided written informed consent.
Disclosure

The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

L-R contributed to the data collection, study design, clinical treatments, and follow-ups. L-R, B-S, Z-SX, and X-B contributed to the data collection and analysis and manuscript preparation. Z-XY, Z-Y, and Z-WD contributed to the supervision of the data quality control and laboratory procedures. L-R, X-B, and Z-WD contributed to the statistical analysis of the data and revision of the manuscript. All authors read and approved the final manuscript. The manuscript was approved by all authors for publication.

Acknowledgments

The authors are grateful to Shanghai Lu-Ming Biotech Co., Ltd. and Dr. Xiaohua Jiang for contributing to revising the manuscript. This study was supported by the National Key Research and Development Project (2019YFA0802600) and the National Natural Science Foundation of China (82171599, 81971333, and 81901543).

References

[1] S. Bocca, E. B. Real, S. Lynch et al., “Impact of serum estradiol levels on the implantation rate of cleavage stage cryopreserved-thawed embryos transferred in programmed cycles with exogenous hormonal replacement,” Journal of Assisted Reproduction and Genetics, vol. 32, no. 3, pp. 395–400, 2015.

[2] R. Trevisan, R. Nosadini, A. Avogaro et al., “Type I diabetes is characterized by insulin resistance not only with regard to glucose, but also to lipid and amino acid metabolism,” The Journal of Clinical Endocrinology and Metabolism, vol. 62, no. 6, pp. 1155–1162, 1986.

[3] C. J. Nolan and M. Prentki, “Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: time for a conceptual framework shift,” Diabetes & Vascular Disease Research, vol. 16, no. 2, pp. 118–127, 2019.

[4] I. Bayasula, A. Iwase, H. Kobayashi et al., “A proteomic analysis of human follicular fluid: comparison between fertilized oocytes and non-fertilized oocytes in the same patient,” Journal of Assisted Reproduction and Genetics, vol. 30, no. 9, pp. 1231–1238, 2013.

[5] Rotterdam EA-SPcwg, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS),” Human Reproduction, vol. 19, no. 1, pp. 41–47, 2004.

[6] Y. Yang, J. Qiao, R. Li, and M. Z. Li, “Is interleukin-18 associated with polycystic ovary syndrome?,” Reproductive Biology and Endocrinology, vol. 9, no. 1, p. 7, 2011.

[7] C. J. Glueck and N. Goldenberg, “Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics,” Metabolism, vol. 92, pp. 108–120, 2019.

[8] R. S. Legro, “Obesity and PCOS: implications for diagnosis and treatment,” Seminars in Reproductive Medicine, vol. 30, no. 6, pp. 496–506, 2012.

[9] F. Dong, D. Deng, H. Chen et al., “Serum metabolomics study of polycystic ovary syndrome based on UPLC-QTOF-MS coupled with a pattern recognition approach,” Analytical and Bioanalytical Chemistry, vol. 407, no. 16, pp. 4683–4695, 2015.

[10] H. Teede, A. Deeks, and L. Moran, “Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan,” BMC Medicine, vol. 8, no. 1, article 41, 2010.

[11] Z. Niu, N. Lin, R. Gu, Y. Sun, and Y. Feng, “Associations between insulin resistance, free fatty acids, and oocyte quality in polycystic ovary syndrome during in vitro fertilization,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 11, pp. E2269–E2276, 2014.

[12] R. Reynoso, L. M. Saltado, and V. Calderon, “High levels of palmitic acid lead to insulin resistance due to changes in the level of phosphorylation of the insulin receptor and insulin receptor substrate-1,” Molecular and Cellular Biochemistry, vol. 246, pp. 155–162, 2003.

[13] T. Matsuoka, H. Shimano, N. Yahagi et al., “Crucial role of a long-chain fatty acid elongase, Elov6, in obesity-induced insulin resistance,” Nature Medicine, vol. 13, no. 10, pp. 1193–1202, 2007.

[14] B. Vessby, I. B. Gustafsson, S. Tengblad, M. Boberg, and A. Andersson, “Desaturation and elongation of fatty acids and insulin action,” Annals of the New York Academy of Sciences, vol. 967, no. 1, pp. 183–195, 2002.

[15] L. D. Roberts, S. Virtue, A. Vidal-Puig, A. W. Nicholls, and J. L. Griffin, “Metabolic phenotyping of a model of adipocyte differentiation,” Physiological Genomics, vol. 39, no. 2, pp. 109–119, 2009.

[16] K. S. McCommis and B. N. Finck, “Mitochondrial pyruvate transport: a historical perspective and future research directions,” The Biochemical Journal, vol. 466, no. 3, pp. 443–454, 2015.

[17] H. Zhao, Y. Zhao, T. Li et al., “Metabolism alteration in follicular fluid: comparison between fertilized oocytes and non-fertilized oocytes in the same patient,” Journal of Assisted Reproduction and Genetics, vol. 30, no. 9, pp. 1231–1238, 2013.
[22] V. Legry, S. Francque, J. T. Haas et al., “Bile acid alterations are associated with insulin resistance, but not with NASH, in obese subjects,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 102, no. 10, pp. 3783–3794, 2017.

[23] Y. G. Cherng, C. C. Tsai, H. H. Chung, Y. W. Lai, S. C. Kuo, and J. T. Cheng, “Antihyperglycemic action of sinapic acid in diabetic rats,” *Journal of Agricultural and Food Chemistry*, vol. 61, no. 49, pp. 12053–12059, 2013.

[24] H. Kikuzaki, M. Hisamoto, K. Hirose, K. Akiyama, and H. Taniguchi, “Antioxidant properties of ferulic acid and its related compounds,” *Journal of Agricultural and Food Chemistry*, vol. 50, no. 7, pp. 2161–2168, 2002.

[25] S. J. Roy and P. S. Mainzen Prince, “Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats,” *European Journal of Pharmacology*, vol. 699, no. 1-3, pp. 213–218, 2013.

[26] E. Hou, Y. Zhao, J. Hang, and J. Qiao, “Metabolomics and correlation network analysis of follicular fluid reveals associations between L-tryptophan, L-tyrosine and polycystic ovary syndrome,” *Biomedical Chromatography*, vol. 35, no. 3, article e4993, 2021.

[27] Y. Zhao, L. Fu, R. Li et al., “Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis,” *BMC Medicine*, vol. 10, no. 1, article 153, 2012.

[28] C. B. Newgard, J. An, J. R. Bain et al., “A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance,” *Cell Metabolism*, vol. 9, no. 4, pp. 311–326, 2009.

[29] T. J. Wang, M. G. Larson, R. S. Vasan et al., “Metabolite profiles and the risk of developing diabetes,” *Nature Medicine*, vol. 17, no. 4, pp. 448–453, 2011.

[30] P. Würtz, M. Tiainen, V. P. Mäkinen et al., “Circulating metabolite predictors of glycemia in middle-aged men and women,” *Diabetes Care*, vol. 35, no. 8, pp. 1749–1756, 2012.